Bioxytran Secures a Source of GMP Quality Camel Hemoglobin

Rhea-AI Summary

Bioxytran (OTCQB: BIXT) has secured a GMP quality source of camel hemoglobin through a partnership with the Heme Foundation in a $10 million Joint Venture to develop a Universal Oxygen Carrier (UOC). Camel hemoglobin was chosen for its unique properties, including higher stability, resilience, and concentration compared to cow hemoglobin, with no risk of mad cow disease. The partnership grants Bioxytran full intellectual property rights for UOC development, which could enhance their leading oxygen transport molecule BXT-25, designed to treat conditions like stroke, dementia, Traumatic Brain Injury, and Alzheimer's Disease. This supply agreement represents a strategic milestone that could accelerate non-dilutive funding and advance oxygen transport technology development.

Positive

• Secured GMP quality source of camel hemoglobin through $10 million Joint Venture with Heme Foundation
• Retains full intellectual property rights for UOC development
• Camel hemoglobin offers superior properties including higher stability and concentration compared to cow alternatives
• Partnership could unlock additional non-dilutive funding opportunities
• Supply agreement strengthens development potential for BXT-25 drug candidate

Negative

• None.

- First use of camel hemoglobin as a universal oxygen carrier

- Unique properties make it an ideal ingredient for oxygen transport

BOSTON, MASSACHUSETTS, June 18, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing drugs to treat stroke, Alzheimer’s disease, and viruses, has a secured a GMP quality source of camel hemoglobin with help from the Heme Foundation.

The Heme foundation, dedicated to solving the worlds blood shortages, is partnered with Bioxytran in a $10 million Joint Venture (JV) to develop a Universal Oxygen Carrier (UOC). Through this collaboration, Bioxtyran now has a long-term source of GMP quality camel hemoglobin – a crucial component for advancing this innovative oxygen transport system. Growing interest in the UOC project is expected to drive increased donations to the foundation. Bioxytran is the Heme Foundation’s primary contractor on the UOC project.

Securing a stable and reliable source of GMP quality hemoglobin is vital to the success of the UOC project. Some of the properties of camel hemoglobin make it the ideal building block because there is no perceived threat of mad cow disease compared to cow hemoglobin. Additionally, the half-life of the hemoglobin is significantly higher than a cow when measured in the final production phase. In general, camels have a higher concentration of hemoglobin in their blood cells along with a higher red blood cell count.

Because camels thrive in harsh climates their hemoglobin is more resilient and maintains oxygen carrying capacity even under high temperatures or salt concentrations. The extreme conditions in which they live adapted their hemoglobin to be much more stable than a cow’s. Studies show that camel hemoglobin exhibits lower fluctuation near the heme binding site which means its more stable and has a nominal impact on the oxygen carrying capacity. These efficiencies could boost the overall impact and scalability of the UOC project.

Under the terms of the JV, Bioxytran retains full intellectual property rights for UOC development, which could unlock millions in research advancements applicable to our leading oxygen transport molecule, BXT-25. The drug was designed to permeate blood clots and improve outcomes in a number of indications that include dementia, stroke, Traumatic Brain Injury (TBI), and Alzheimer’s Disease.

“This supply agreement is a major milestone in our long-term strategy for BXT-25 and the UOC,” said David Platt, CEO of Bioxtyran Inc. “Having a reliable supplier not only strengthens our work with the Heme Foundation but could also accelerate non-dilutive funding, fueling innovation in oxygen transport technology. Camel hemoglobin offers powerful advantages and we are excited about this new supplier relationship.”

About the Heme Foundation

The Heme Foundation is a 501(c)(3) nonprofit founded in 2021 and based in Bethlehem, Pennsylvania. Their mission is to provide the world with an alternative for blood transfusions using UOC to eliminate the need for a complex supply chain and to abate the cold chain storage requirements for lifesaving blood transfusions. https://hemefoundation.org/donate/

About Bioxytran, Inc.

Bioxytran, Inc. is at the forefront of developing complex carbohydrate-based therapeutics to address critical unmet medical needs in its three core platform technologies. These include virology, cancer metastasis, and oxygen transport. In addition to ProLectin-M, Bioxytran is advancing programs for pulmonary fibrosis and stroke treatment. When utilized by paramedics at the time of diagnosis BXT-25 has the possibility of reducing what is known as the time until needle by over 90%. For more information, visit www.bioxytraninc.com

Investor Relations
Michael Sheikh
509-991-0245
mike.sheikh@bioxytraninc.com

Forward-Looking Statements

This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran’s actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.

FAQ

What is the significance of Bioxytran (BIXT) securing camel hemoglobin supply?

The secured GMP quality camel hemoglobin supply is crucial for Bioxytran's $10M Joint Venture to develop a Universal Oxygen Carrier, offering superior properties and stability compared to alternatives, while supporting their BXT-25 drug development program.

How does camel hemoglobin compare to cow hemoglobin for Bioxytran's (BIXT) UOC project?

Camel hemoglobin is more stable, has higher concentration, better resilience to extreme conditions, and poses no mad cow disease risk compared to cow hemoglobin, making it ideal for the UOC project.

What are the potential applications of Bioxytran's (BIXT) BXT-25 drug?

BXT-25 is designed to treat multiple conditions by permeating blood clots, including stroke, dementia, Traumatic Brain Injury (TBI), and Alzheimer's Disease.

What is the partnership structure between Bioxytran (BIXT) and the Heme Foundation?

Bioxytran and the Heme Foundation have formed a $10 million Joint Venture, where Bioxytran serves as the primary contractor and retains full intellectual property rights for UOC development.

How will the camel hemoglobin supply agreement impact Bioxytran's (BIXT) funding?

The supply agreement could accelerate non-dilutive funding opportunities and strengthen Bioxytran's work with the Heme Foundation, supporting innovation in oxygen transport technology.